Liminal BioSciences is a clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using our drug discovery platform and data-driven approach. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market (LMNL).
On October 15, 2021 the Company closed on the divestment of the remainder of its plasma-derived therapeutics business to focus solely on its small molecule therapeutics pipeline.
Loading...
No Records Found
Sorry, no records were found. Please adjust your search criteria and try again.
We use cookies to personalize content and ads, to provide social media features and to analyze our website traffic. We also share information about your use of our website with our social media, advertising, and analytics partners. Read more about how we use cookies by clicking on 'Privacy Policy'. Click the "I agree" button to continue to use this site.I agreePrivacy Policy
